Sarepta ($SRPT) Misrepresented ELEVIDYS Efficacy, Concealed Patient Deaths, and Misled Market Case
$SRPT investors filed a claim against Sarepta Therapeutics for concealing safety risks and misrepresenting regulatory progress for its gene therapy ELEVIDYS. The company allegedly downplayed critical setbacks, including trial holds, safety concerns, and patient deaths—while overstating its ability to expand ELEVIDYS use.
After revelations about adverse events, halted trials, and regulatory delays, $SRPT dropped a combined 45.8%, including a 15.8% drop on March 21, 2024, and 30% on May 29, 2024.
$SRPT investors can join this case to be notified about potential recovery.
Case Details:
Between October 27, 2022 and May 28, 2024, Sarepta told investors that ELEVIDYS was progressing toward expanded FDA approval for older Duchenne muscular dystrophy patients. Executives described the therapy as a breakthrough with a strong safety profile and regulatory momentum.
In reality, the company concealed multiple adverse events, including trial patient deaths. Sarepta failed to inform the market that the FDA had paused one of its trials due to a fatal reaction. It also misrepresented the likelihood of expanded approval, despite regulatory pushback and unresolved safety concerns.
On March 20, 2024, STAT News revealed the FDA had placed a clinical hold on a key ELEVIDYS trial following a patient death. $SRPT dropped 15.8% the next day. Then on May 28, 2024, Sarepta disclosed the FDA had rejected its request to expand ELEVIDYS to older DMD patients—contradicting months of investor guidance. The stock plunged another 30%.
Based on these events, $SRPT investors filed a claim against Sarepta Therapeutics, accusing the company of the following:
It concealed patient deaths and safety problems in its gene therapy trials.
It misled investors about FDA interactions and the likelihood of broader approval.
Considering all the representations, investors believe Sarepta overstat
ed ELEVIDYS’s commercial and regulatory prospects to support its valuation.